Sanjay Shrivastava, Ph.D.

Innova Vascular, Inc. has developed thrombectomy products for treating cardiovascular clots. It received FDA clearance for its Malibu Aspiration Catheter System and Laguna Clot Retriever System for peripheral vascular use. The products are in human use in the USA.

BlackSwan Vascular is a company that developed the first liquid embolic agent approved in the USA for a peripheral vascular use. It received PMA approval by the US FDA in April 2023. In 2020, BlackSwan announced a strategic alliance with Sirtex Mecical, Inc. BlackSwan was acquired by Sirtex Medical's parent company "Grand China Pharmaceuticals Ltd" in April 2023.

Cardiovascular and Specialty Solutions; Medical Device Companies; served on the leadership team of Biosense Webster, Inc. (electrophysiology ablation product company within J&J Medical Devices) representing business development. Responsibilities included acquisitions, investments, as well as distribution and licensing deals. Left the company after 2 years of rewarding career to focus on the startup company that I founded.

BTG, plc, now acquired by Boston Scientific, was an interventional medical device and specialty pharmaceutical company. It had about $800MM in annual revenue and was traded at the London Stock Exchange. I was located in Irvine, CA. My role was to develop strategy for its interventional oncology business and manage upstream marketing.

As a part of Medtronic's Cardiac and Vascular Group (CVG), I served on the leadership team of a business, where I was responsible for WW downstream and upstream marketing for a rapidly growing franchise. Prior to being part of CVG, I was part of the neurovascular organization. My team’s responsibilities included: • Leading the creation and execution of our global commercial strategy • Working with regional business units to implement global product launches • Leading messaging, promotion and pricing strategy • Managing and executing trade-show strategy • Working with medical affairs to develop and implement peer-to-peer messaging strategies • Management of key opinion leaders (KOLs) • Supporting the US sales as well as the OUS regional teams • Leading the global portfolio strategy including making recommendations for decisions on R&D and clinical investments as well as external alliances and acquisitions • Supporting new product development projects • Developing market models and gathering competitive intelligence • Supporting the evaluation of external alliance and acquisition targets For my work in initiating and growing this franchise, I was awarded the prestigious presidents-club award in 2015 and national impact award in 2013. Additionally, I was selected via an anonymous survey of employees among a few leaders from the entire company for demonstrating results using innovative approaches in 2013.

Led the development of a breakthrough product called Solitaire FR revascularization device. This device became a key enabler in interventional treatments becoming the standard of care for acute ischemic stroke (AIS). R&D and process development teams reported directly to me while I also managed the full cross functional team involved in this project through various development and commercialization phases. I managed a staff of up to 35 engineers, managers, and technicians including hiring 10 new employees. This team was awarded the best project team award in 2012. Additionally, I was awarded innovator of the year in 2008. My work included partnering with numerous neuro-Interventionalist to enable a successful product development and launch. Additionally, I led the execution of a licensing agreement for an important accessory product from an outside company. I was also part of the team that evaluated numerous early stage technologies as acquisition target for our business.

I worked at Abbott Vascular at Redwood City, CA and Santa Clara, CA locations (Bay Area) during this period. 2006-07, I was responsible for initiating and managing the Absolute Pro peripheral stent R&D program. I oversaw this program, which had about 50 personnel from R&D, process development, manufacturing engineering, supply chain, quality, regulatory, clinical and marketing on the team across Santa Clara, CA and Temecula, CA locations. 2004-06, I was the site leader for Redwood City, CA site for peripheral stents R&D. I managed a team of up to 17 engineers and technicians (including hiring 8 people) and brought Xceed self expanding stent (including its novel delivery system) development to completion. I also led a multi-site program involving Redwood City, CA, Rangendingen, Germany and Beringen, Switzerland to explore a peripheral drug eluting stent program based on Xpert stent platform. I represented Abbott on a peripheral stent consortium, which was led by Stanford University and SRI International with participation from Abbott, Medtronic, Cook, Boston Scientific and the FDA. Additionally, I continued to serve on ASTM committee to develop cardiovascular test standards. During 2003-04, I led process development activities associated with our coronary drug eluting stent program.

During 2002-03, I managed the Nitinol Center of Excellence at Edwards Lifesciences including setting up all Nitinol processing and testing facilities. This included laser cutting, electro-polishing, surface preparation and finishing, fatigue testing, corrosion testing etc. The work included early stage prototyping work on trans-catheter heart valve as well as a few other products. I had two engineers directly reporting to me while I managed a cross-functional team of up to 4 engineers. During 2000-02, I was part of the vascular group leading the re-design of an endovascular product. I managed the work of up to 6 engineers and technicians to redesign this product, which received timely approval of IDE and a clinical trial could be initiated. I also served on the ASTM committee to develop cardio-vascular test standards and visited FDA as part of a small team to have a pre-submission meeting for our IDE approval.